Degradation pathways of a corticotropin-releasing factor antagonist in solution and solid states

Journal of Pharmaceutical Sciences

Volumn 98, Issue 8, 2009, Pages 2636-2647

  Badawy, S ^a   Hussain, M ^a   Zhao, F ^a,b   Ye, Q ^a   Huang, Y ^a   Palaniswamy, V ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b ST JOHN FISHER COLLEGE   (United States)

Author keywords

Chemical stability; Solid dosage form; Solid state stability; Stability; Stabilization

Indexed keywords

CORTICOTROPIN RELEASING FACTOR ANTAGONIST; TRIAZINE DERIVATIVE;

ARTICLE; DEGRADATION; DRUG FORMULATION; DRUG MANUFACTURE; DRUG STABILITY; HUMIDITY; HYDROLYSIS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE; PHYSICAL PHASE; SOLID; SOLUTION AND SOLUBILITY; TABLET;

EID: 68249130129     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21637     Document Type: Article

References (16)

1. Holsboer F. 2003. Corticotropin-releasing hormone modulators and depression. Curr Opin Investig Drugs 4:46-50.
2. Claes S, Villafuerte S, Forsgren T, Sluijs S, Del-Favero J, Adolfsson R, Van-Broeckhoven C. 2003. The corticotropin-releasing hormone binding protein is associated with major depression in a population from Northern Sweden. Biol Psychiatry 54: 867-872. (Pubitemid 37311347)
3. Hall IH, Taylor K, Izydore RA, Coleman DE, Mitchell JA, Cummings R. 1998. The cytotoxic action of 1,3,5-triazabicyclohexane-2,4-diones and 1,3,5-triazine-4,6-(1H,5H)-diones in murine and human tumor cells. Pharmazie 53:398-405. (Pubitemid 28293596)
4. Brzozowski Z, Saczewski F. 2002. Synthesis and antitumor activity of novel 2-amino-4-(3,5,5-trimethyl-2-pyrazolino)-1,3,5-triazine derivatives. Eur J Med Chem 37:709-720.
5. Coley HM. 1997. N-(hydroxymethyl)melamines. Gen Pharmacol 28:177-182.
6. Terao T, Matsubara T, Kaga J, Kobatake H, Naito S. 1995 improvement of gastrointestinal absorption of a new oral xanthine oxidase/dehydrogenase inhibitor, sodium (+)-8-(3-methoxy-4-phenylsulfinylphenyl) pyrazolo(1,5-a)-1,3, 5-triazine-4-olate monohydrate, in rats and dogs. J Pharm Sci Technol 55:36-43.
7. Cumber AJ, Ross WC. 1977. Analogues of hexamethylmelamine. The anti-neoplastic activity of derivatives with enhanced water solubility. Chem Biol Interact 17:349-357.
8. Pande A, Saxena VK. 1985. Synthesis and antiviral activity of some new 6-aryl-7-arylazo-4-phenyl-2Hthiazolo (3,2-alpha)-1,3,5-triazine-2-thiones. Indian J Pharm Sci 47:227-229.
9. Notari RE, DeYoung JL. 1975. Kinetics and mechanisms of degradation of the antileukemic ageny 5-azacytidine in aqueous solutions. J Pharm Sci 64:1148-1157.
10. Gilligan PJ, Baldauf C, Cocuzza A, Chidester D, Zaczek R, Fitzerald LW, McElroy J, Smith MA, Shen H-SL, Saye JA, Christ D, Trainor G, Robertson DW, Hartig P. The discovery of 4-(3-pentylamino)-2, 7-dimethyl-8-dimethyl-8-(2- methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine: A corticotropin-releasing factor (hCFR) antagonist. Bioorg Med Chem 8:181-189.
11. Sherbine JP, Pack SK, Pesti JA, Yule RE, McNulty KC. 2005. Process for the Preparation of Pyrazolo[1,5-a]-1,3,5-triazines and Intermediates thereof. US Patent 0143380 issued June 30.
12. Gilligan PJ, Rabel-Riley SR, Meenan PA. 2005. Salt and crystalline form thereof of a corticotropin releasing factor receptor antagonist. US Patent 0113375 issued May 26, 2005.
13. 2-diarylamidines. Chem Pharm Bull 38:590-596.
14. Waterman KC, Adami RC, Alsante KM, Antipas AS, Arenson DR, Carrier R, Hong J, Landis MS, Lombardo F, Shah JC, Shalaev E, Smith SW, Wang H. 2002. Hydrolysis in pharmaceutical formulations. Pharm Dev Technol 7:113-146.
15. Badawy SIF, Vickery R, Shah K, Hussain M. 2004. Effect of processing and formulation variables on the stability of a salt of a weakly basic drug candidate. Pharm Dev Technol 9:239-245. (Pubitemid 39166277)
16. March J. 1992. Advanced organic chemistry: Reactions, mechanisms, and structure. 4th edition. New York: John Wiley & Sons Ltd. p. 885.